These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 18813347)
1. Decoy receptor 3 is a prognostic factor in renal cell cancer. Macher-Goeppinger S; Aulmann S; Wagener N; Funke B; Tagscherer KE; Haferkamp A; Hohenfellner M; Kim S; Autschbach F; Schirmacher P; Roth W Neoplasia; 2008 Oct; 10(10):1049-56. PubMed ID: 18813347 [TBL] [Abstract][Full Text] [Related]
2. The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma. Weissinger D; Tagscherer KE; Macher-Göppinger S; Haferkamp A; Wagener N; Roth W Mol Cancer; 2013 Oct; 12(1):120. PubMed ID: 24107265 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Macher-Goeppinger S; Aulmann S; Tagscherer KE; Wagener N; Haferkamp A; Penzel R; Brauckhoff A; Hohenfellner M; Sykora J; Walczak H; Teh BT; Autschbach F; Herpel E; Schirmacher P; Roth W Clin Cancer Res; 2009 Jan; 15(2):650-9. PubMed ID: 19147771 [TBL] [Abstract][Full Text] [Related]
4. [Relationship between expression of decoy receptor 3 and apoptosis in hepatocellular carcinoma]. Chen G; Luo DZ; Wang Y; Liao ZL; Zhang MY Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):113-7. PubMed ID: 17493386 [TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580 [TBL] [Abstract][Full Text] [Related]
6. Death decoy receptor overexpression and increased malignancy risk in colorectal cancer. Zong L; Chen P; Wang DX World J Gastroenterol; 2014 Apr; 20(15):4440-5. PubMed ID: 24764685 [TBL] [Abstract][Full Text] [Related]
7. Functional characterisation of decoy receptor 3 in Crohn's disease. Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087 [TBL] [Abstract][Full Text] [Related]
8. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Lin WW; Hsieh SL Biochem Pharmacol; 2011 Apr; 81(7):838-47. PubMed ID: 21295012 [TBL] [Abstract][Full Text] [Related]
9. Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Chen G; Luo D Ups J Med Sci; 2008; 113(3):297-304. PubMed ID: 18991242 [TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of decoy receptor 3 in human breast cancer: relevance to lymphangiogenesis. Wu Q; Zheng Y; Chen D; Li X; Lu C; Zhang Z J Surg Res; 2014 May; 188(2):459-65. PubMed ID: 24612949 [TBL] [Abstract][Full Text] [Related]
11. Role of prognostic biomarker decoy receptor 3 and immunomodulation in kidney diseases. Weng SC; Tarng DC J Chin Med Assoc; 2019 Sep; 82(9):680-684. PubMed ID: 31356560 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of expression and amplification of the DcR3 gene in pancreatic carcinomas. Zhou J; Song SD; Li DC; Zhou J; Zhu DM; Zheng SY Asian Pac J Cancer Prev; 2012; 13(2):719-24. PubMed ID: 22524850 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. Mignogna C; Staibano S; Altieri V; De Rosa G; Pannone G; Santoro A; Zamparese R; D'Armiento M; Rocchetti R; Mezza E; Nasti M; Strazzullo V; Montanaro V; Mascolo M; Bufo P BMC Cancer; 2006 Dec; 6():293. PubMed ID: 17177989 [TBL] [Abstract][Full Text] [Related]
15. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells. Zhang Y; Li D; Zhao X; Song S; Zhang L; Zhu D; Wang Z; Chen X; Zhou J Biochem Biophys Res Commun; 2015 Aug; 463(4):1144-51. PubMed ID: 26102031 [TBL] [Abstract][Full Text] [Related]
16. DcR3 promotes hepatoma cell migration by downregulating E-cadherin expression. Zhang H; Chen X; Li D; Cui L; Li X; Ye X; Wan X Oncol Rep; 2017 Jul; 38(1):377-383. PubMed ID: 28560426 [TBL] [Abstract][Full Text] [Related]
17. Decoy Receptor 3 Expression Is Associated With Wild-Type EGFR Status, Poor Differentiation of Tumor, and Unfavorable Patient Outcome. Chang WC; Yeh YC; Ho HL; Hsieh SL; Chou TY Am J Clin Pathol; 2019 Jul; 152(2):207-216. PubMed ID: 31077284 [TBL] [Abstract][Full Text] [Related]
18. Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions. Hsieh SL; Lin WW J Biomed Sci; 2017 Jun; 24(1):39. PubMed ID: 28629361 [TBL] [Abstract][Full Text] [Related]
19. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma. Bedewy AM; Elgammal MM; Bedewy MM; El-Maghraby SM Ann Hematol; 2013 Oct; 92(10):1359-67. PubMed ID: 23652586 [TBL] [Abstract][Full Text] [Related]
20. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Connor JP; Felder M Gynecol Oncol; 2008 Nov; 111(2):330-5. PubMed ID: 18723214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]